反相高效液相色谱法测定(E)-3-(4-((3,5,6-三甲基吡嗪-2-基)甲氧基)-3-甲氧基苯基)丙烯酸在SD大鼠血浆中的浓度
doi: 10.3969/j.issn.1006-0111.2012.01.011
Determination of (E)-3-(3-methoxy-4-((3,5,6-trimethylpyrazin-2-yl) methoxy)phenyl)acrylate in rat plasma by RP-HPLC
-
摘要: 目的 建立测定SD大鼠血浆中(E)-3-(4-((3,5,6-三甲基吡嗪-2-基)甲氧基)-3-甲氧基苯基)丙烯酸浓度的反相高效液相色谱(LC-UV)方法,并用于其在SD大鼠体内的药动学研究。方法 采用Diamonsil-C18(2)柱(100 mm×4.6 mm,5 μm),以乙腈:水(含5 mM的醋酸铵,用醋酸调节pH至4.0)=30:70为流动相,测定70只SD大鼠单剂量尾静脉给药15 mg/kg后不同时刻血浆中药物的浓度,并由此计算其在SD大鼠体内的药动学参数。结果 SD大鼠Abstract: Objective To establish a method for determination of (E)-3-(3-methoxy-4-((3,5,6-trimethylpyrazin-2-yl) methoxy)phenyl)acrylate in plasma of SD rats by RP-HPLC. Methods The chromatographic separation was performed on a Diamonsil-C18 column(100 mm×4.6 mm,5 μm) with the mobile phase consisting of acetonitrile/5 mM ammonium acetate buffer(pH 4.0)(30/70,v/v). The single intravenous injection of (E)-3-(3-methoxy-4-((3,5,6-trimethylpyrazin-2-yl) methoxy)phenyl)acrylate was given to 70 SD rats to study the pharmacokinetics. Results The intra-run and inter-run RSD were less than 15%. The pharmacokinetics parameters were as follows: Cmax was 35.60 μg/ml , t1/2 was 3.36 h, AUC0~12 was 17.12 μg h/ml, AUC0~∞ was 17.72μg h/ml. Conclusion The method was simple and accurate, which could be used to separation and determination of (E)-3-(3-methoxy-4-((3,5,6-trimethylpyrazin-2-yl) methoxy)phenyl)acrylate.
-
[1] 潘赞红, 金 鑫. 川芎嗪与阿魏酸配伍对大鼠心肌缺血再灌注损伤心肌的保护作用[J]. 天津医药. 2008, 36(10): 796. [2] 杨家荣, 张密霞, 常亮堂, 等. 川芎嗪、阿魏酸及其配伍对心肌缺血再灌注模型大鼠的保护作用及对黏附分子的影响[J]. 中草药. 2008, 39(7): 1054. [3] 杜 希. 氯吡格雷的药理作用与临床评价[J]. 首都医药. 2002, 7: 44. [4] 李 琳, 张临洪, 徐武平. 氯吡格雷联合奥扎格雷钠治疗后循环脑梗死的临床疗效观察[J].中国临床神经外科杂志. 2010, 15(8): 474. [5] 王茜莎, 潘雪刁, 张德志, 等. 奥扎格雷钠对心肌缺血的保护作用研究[J]. 广东药学院学报. 2010, 26(3): 292.
计量
- 文章访问数: 2979
- HTML全文浏览量: 162
- PDF下载量: 538
- 被引次数: 0